Skip to main content

Table 1 Baseline characteristics and demographics

From: Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study

 

Tadalafil (n = 45)

Placebo (n = 23)

P-value*

Age (years)

61.80 ± 7.25

58.87 ± 8.99

0.151

IIEF-5

10.47 ± 4.55

9.57 ± 4.11

0.428

IPSS

13.98 ± 5.77

14.47 ± 8.08

0.231

Waist circumference (cm)

86.89 ± 8.96

89.67 ± 6.21

0.187

Body mass index (kg/m2)

25.51 ± 3.05

26.59 ± 3.69

0.202

Systolic BP (mmHg)

127.84 ± 14.51

129.70 ± 17.57

0.645

Diastolic BP (mmHg)

87.34 ± 11.74

86.68 ± 8.73

0.538

HbA1c (%)

6.83 ± 0.77

6.77 ± 0.58

0.747

Fasting plasma glucose (mg/dL)

128.02 ± 24.95

120.70 ± 18.34

0.203

Insulin (IU/mL)

9.13 ± 9.14

10.04 ± 8.66

0.694

C-peptide (ng/mL)

1.77 ± 0.92

1.70 ± 0.77

0.686

HOMA-IR

3.05 ± 3.32

2.92 ± 2.51

0.870

Total cholesterol (mg/dL)

142.31 ± 28.05

140.43 ± 31.98

0.804

Triglyceride (mg/dL)

140.40 ± 123.55

144.61 ± 54.57

0.877

HDL-C (mg/dL)

44.42 ± 8.13

43.87 ± 9.50

0.803

LDL-C (mg/dL)

76.89 ± 23.32

74.48 ± 26.29

0.701

BUN (mg/dL)

16.10 ± 4.14

15.36 ± 5.84

0.549

Creatinine (mg/dL)

1.0 ± 0.207

1.01 ± 0.29

0.858

eGFR (mL/min/1.73 m2)

80.88 ± 14.96

83.49 ± 22.39

0.618

AST (IU/L)

27.09 ± 10.38

27.91 ± 13.51

0.781

ALT (IU/L)

28.56 ± 11.52

28.57 ± 10.24

0.997

Diabetes duration (years)

9.47 ± 6.33

8.13 ± 5.57

0.395

Current smoker (%)

14 (31.1)

7 (30.4)

0.954

Current alcohol drinker (%)

27 (62.2)

16 (69.6)

0.549

Medication treatment for, n (%)

 Hypertension

30 (66.7)

17 (73.9)

0.541

 Dyslipidemia

34 (75.6)

17 (73.9)

0.882

 Benign prostate hyperplasia

20 (44.4)

9 (39.1)

0.675

Number of concomitant antihyperglycemic medication, n (%)

 1

3 (6.7)

3 (13.1)

0.380

 2

22 (48.9)

11 (47.8)

0.933

 ≥ 3

20 (44.4)

9 (39.1)

0.675

Antihyperglycemic drugs

 Sulfonylurea (%)

17 (37.8)

9 (39.1)

0.913

 Metformin (%)

40 (88.9)

20 (86.9)

0.814

 Dipeptidyl peptidase 4 inhibitors (%)

38 (84.4)

16 (69.6)

0.151

 SGLT 2 inhibitors (%)

11 (24.4)

7 (30.4)

0.596

Antihypertensive drugs

 Angiotensin receptor blockers (%)

25 (55.5)

16 (69.9)

0.264

 Calcium channel blockers (%)

15 (33.3)

11 (39.1)

0.244

 Diuretics (%)

6 (13.3)

5 (21.7)

0.373

 Beta-receptor blockers (%)

6 (13.3)

3 (13)

0.973

  1. Data are presented as mean ± standard deviation or proportion (%)
  2. IIEF, International Index of Erectile Function; IPSS, International Prostate Symptom Score; BP, blood pressure; HOMA-IR, homeostatic model assessment-insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; SGLT, sodium-glucose cotransporter
  3. *P values were derived using paired Student’s t-test or Pearson’s Chi-square test
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us